摘要
目的观察长期吸入沙美特罗替卡松对稳定期重度COPD患者肺功能、血气指标、TNF-α及生活质量等的影响。方法选取在我院治疗的78例重度COPD患者随机分为对照组39例、试验组39例。对照组口服茶碱缓释胶囊并按需使用短效支扩剂;试验组在此基础上给予沙美特罗替卡松(50/500μg)吸入治疗。对两组治疗1个月、6个月的肺功能指标、血气指标、痰液TNF-α水平及SGRQ评分改善进行统计比较。结果试验组6个月后FEV1及FEV1/FVC较对照组有明显改善;试验组呼吸困难明显改善;治疗后1个月、6个月时试验组的血气、肺功能指标及SGRQ评分结果均优于对照组,而试验组痰液TNF-α水平均低于对照组,有显著性差异(P<0.05)。结论沙美特罗替卡松吸入治疗稳定期重度COPD,能够显著改善肺功能,明显缓解临床症状,显著提高患者生活质量。
Objective To observe the clinical effect of long-term inhalation of salmeterol/fluticasone propionate（SFP） on lung function,blood gas indexes（SaO2,PaO2）,TNF-α level,and quality of life（QOL） of patients with severe COPD at stable phase.Methods 78 patients with severe COPD were randomly and evenly divided into the treatment group and the control group.All patients were orally given theophylline SR and short-term effect bronchodilators if necessary,and the treatment group was added SFP（50 /500 μg） inhalation twice a day.Indexes of lung function,TNF-α level of induced sputum and SGRQ scores pre-and post-treatment were observed and analyzed.Results 6 months after the treatment,FEV1,EVC and dyspnea were better improved in treatment group than in the control group,and the improvement of SaO2,PaO2,lung function,and SGRQ scores was more pronounced in the treatment group than in the control group.The level of TNF-α was significantly lower in the treatment group than in the control group（P〈0.05）.Conclusion The inhalation of SFP can significantly improve the lung function,clinical symptoms and QOL of patients with severe COPD,which is an effective measures for treatment and prevention in the progression of COPD.
出处
《临床肺科杂志》
2013年第8期1397-1398,共2页
Journal of Clinical Pulmonary Medicine
